This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Studies in support of biosimilarity in healthy volunteers
PD=pharmacodynamic; PK=pharmacokinetic.
Studies in support of biosimilarity in healthy volunteers
Eligible,§ commercially insured patients|| may pay as little as $0 per NYVEPRIA treatment.¶ See full Terms and Conditions below.
FOR LIVE, PERSONALIZED SUPPORT
Call 1-877-744-5675 (Monday-Friday, 8 AM-8 PM ET)
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.
Contraindications
NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use
NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.